Materiały źródłowe

• #1 Myelofibrosis: Symptoms, Causes, Diagnosis, and Treatment

  https://www.webmd.com/cancer/myelofibrosis-causes-risk-factors

  Theres no way to prevent myelofibrosis. But researchers are trying to learn more about it. […] Your treatment will depend on your case, including your symptoms. If you dont have any, your doctor might recommend waiting and watching for changes. […] See your doctor regularly to check your blood for any problems. About 20% of people with myelofibrosis could get acute myeloid leukemia, a kind of cancer thats harder to treat.

• #2

  https://www.texasoncology.com/cancer-blood-disorders/cancer-facts/primary-myelofibrosis

  MF cannot be prevented. Research is underway to learn more about how the disease develops.

• #3 Myelofibrosis: Symptoms, Causes, Diagnosis, and Treatment

  https://www.webmd.com/cancer/myelofibrosis-causes-risk-factors

  Theres no way to prevent myelofibrosis. But researchers are trying to learn more about it. […] Your treatment will depend on your case, including your symptoms. If you dont have any, your doctor might recommend waiting and watching for changes. […] See your doctor regularly to check your blood for any problems. About 20% of people with myelofibrosis could get acute myeloid leukemia, a kind of cancer thats harder to treat.

• #4 Primary myelofibrosis – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/myeloproliferative-neoplasms/primary-myelofibrosis/

  Primary myelofibrosis is a rare chronic disorder diagnosed in an estimated 1 per 100,000 population. […] Long-term exposure to high levels of benzene or very high doses of ionising radiation may increase the risk of primary myelofibrosis in a small number of cases. […] For others treatment is largely supportive and is aimed at preventing complications due to low blood counts and an enlarged spleen (splenomegaly). This involves making every effort to improve your quality of life, by relieving any symptoms of anaemia or an enlarged spleen, and preventing and treating any complications that might arise from your disease or its treatment. […] Antibiotics may be needed to prevent and treat any infections. […] JAK2 inhibitors work by blocking the activity of the JAK2 protein, which may lead to a reduction in splenomegaly and decreased symptoms. They also work in patients with myelofibrosis without the JAK2 mutation.

• #5

  https://www.nccs.com.sg/patient-care/conditions-treatments/myelofibrosis

  Myelofibrosis – How to prevent? Many patients with myelofibrosis are recognized incidentally during routine blood test or blood counts testing for other disorders. Currently there are also no proven preventive strategies for essential thrombocythemia. However, adopting a healthy lifestyle may help to prevent disease. This includes: Eating a diet rich in fruits and vegetables […] Quitting or not starting smoking […] Limiting alcohol consumption […] Regular exercise.

• #6

  https://www.nccs.com.sg/patient-care/conditions-treatments/myelofibrosis

  Myelofibrosis – How to prevent? Many patients with myelofibrosis are recognized incidentally during routine blood test or blood counts testing for other disorders. Currently there are also no proven preventive strategies for essential thrombocythemia. However, adopting a healthy lifestyle may help to prevent disease. This includes: Eating a diet rich in fruits and vegetables […] Quitting or not starting smoking […] Limiting alcohol consumption […] Regular exercise.

• #7

  https://link.springer.com/article/10.1007/s11899-024-00729-8

  Myelofibrosis is a progressive myeloproliferative neoplasm (MPN) that generally produces burdensome symptoms and ultimately leads to worse overall survival than that observed in healthy controls or patients with other MPNs. […] Multiple studies have demonstrated that treating MF earlier in the disease course, while the patient is still at int-1 risk status or as soon as possible after diagnosis for intermediate and high risk, may be beneficial to patients, resulting in higher relative efficacy and lower toxicity compared with treating later in the disease course. […] This review provides guidance and a discussion of best practices for early management of patients with overt MF, including treatment early in the disease course and the importance of initiating treatment promptly rather than watch-and-wait approaches.

• #8 Early Myelofibrosis Treatment: Key Considerations – HealthTree for Myelofibrosis

  https://healthtree.org/myelofibrosis/community/articles/early-intervention-in-myelofibrosis

  When active treatment is given to myelofibrosis patients within 12 months of their diagnosis, they have significantly lived longer and experienced fewer disease symptoms than those who receive treatment later. […] Benefits of early intervention and treatment include: […] Patients who start treatment earlier experience higher responses to the treatment and lower toxicity than people starting treatment in a more advanced stage of myelofibrosis. […] Notably, Dr. Prithviraj Bose, an MD Anderson lymphoma doctor specializing in myelofibrosis, shares, There is little to no benefit to delaying active treatment in patients with symptomatic lower-risk MF. […] While earlier intervention does take careful consideration on part of the healthcare provider, it can have significantly positive effects on those with low-risk myelofibrosis and should be seriously considered for those patients who are interested in being treated.

• #9 Early Myelofibrosis Treatment: Key Considerations – HealthTree for Myelofibrosis

  https://healthtree.org/myelofibrosis/community/articles/early-intervention-in-myelofibrosis

  When active treatment is given to myelofibrosis patients within 12 months of their diagnosis, they have significantly lived longer and experienced fewer disease symptoms than those who receive treatment later. […] Benefits of early intervention and treatment include: […] Patients who start treatment earlier experience higher responses to the treatment and lower toxicity than people starting treatment in a more advanced stage of myelofibrosis. […] Notably, Dr. Prithviraj Bose, an MD Anderson lymphoma doctor specializing in myelofibrosis, shares, There is little to no benefit to delaying active treatment in patients with symptomatic lower-risk MF. […] While earlier intervention does take careful consideration on part of the healthcare provider, it can have significantly positive effects on those with low-risk myelofibrosis and should be seriously considered for those patients who are interested in being treated.

• #10 Early Myelofibrosis Treatment: Key Considerations – HealthTree for Myelofibrosis

  https://healthtree.org/myelofibrosis/community/articles/early-intervention-in-myelofibrosis

  When active treatment is given to myelofibrosis patients within 12 months of their diagnosis, they have significantly lived longer and experienced fewer disease symptoms than those who receive treatment later. […] Benefits of early intervention and treatment include: […] Patients who start treatment earlier experience higher responses to the treatment and lower toxicity than people starting treatment in a more advanced stage of myelofibrosis. […] Notably, Dr. Prithviraj Bose, an MD Anderson lymphoma doctor specializing in myelofibrosis, shares, There is little to no benefit to delaying active treatment in patients with symptomatic lower-risk MF. […] While earlier intervention does take careful consideration on part of the healthcare provider, it can have significantly positive effects on those with low-risk myelofibrosis and should be seriously considered for those patients who are interested in being treated.

• #11 Early Myelofibrosis Treatment: Key Considerations – HealthTree for Myelofibrosis

  https://healthtree.org/myelofibrosis/community/articles/early-intervention-in-myelofibrosis

  When active treatment is given to myelofibrosis patients within 12 months of their diagnosis, they have significantly lived longer and experienced fewer disease symptoms than those who receive treatment later. […] Benefits of early intervention and treatment include: […] Patients who start treatment earlier experience higher responses to the treatment and lower toxicity than people starting treatment in a more advanced stage of myelofibrosis. […] Notably, Dr. Prithviraj Bose, an MD Anderson lymphoma doctor specializing in myelofibrosis, shares, There is little to no benefit to delaying active treatment in patients with symptomatic lower-risk MF. […] While earlier intervention does take careful consideration on part of the healthcare provider, it can have significantly positive effects on those with low-risk myelofibrosis and should be seriously considered for those patients who are interested in being treated.

• #12

  https://link.springer.com/article/10.1007/s11899-024-00729-8

  Data exist suggesting that active treatment may inhibit progression of PV/ET to MF in the first place. […] Taken together, these data highlight a possible role for early treatment with ruxolitinib, particularly in the more indolent MPN phases to help prevent or delay disease progression to MF. […] In my practice, we prefer active treatment with ruxolitinib for symptomatic patients with lower-risk MF, consistent with recommendations from the National Comprehensive Cancer Network (NCCN). […] Supporting clinical trial data for ruxolitinib use in patients with int-1 risk MF are shown in Table 2. […] The clinical benefit of initiating treatment with ruxolitinib in patients with int-2 or high-risk MF as soon as possible after diagnosis, rather than delaying treatment, has been demonstrated in the COMFORT studies as well as in other clinical trials and real-world studies.

• #13

  https://link.springer.com/article/10.1007/s11899-024-00729-8

  Data exist suggesting that active treatment may inhibit progression of PV/ET to MF in the first place. […] Taken together, these data highlight a possible role for early treatment with ruxolitinib, particularly in the more indolent MPN phases to help prevent or delay disease progression to MF. […] In my practice, we prefer active treatment with ruxolitinib for symptomatic patients with lower-risk MF, consistent with recommendations from the National Comprehensive Cancer Network (NCCN). […] Supporting clinical trial data for ruxolitinib use in patients with int-1 risk MF are shown in Table 2. […] The clinical benefit of initiating treatment with ruxolitinib in patients with int-2 or high-risk MF as soon as possible after diagnosis, rather than delaying treatment, has been demonstrated in the COMFORT studies as well as in other clinical trials and real-world studies.

• #14 Prefibrotic myelofibrosis: treatment algorithm 2018 | Blood Cancer Journal

  https://www.nature.com/articles/s41408-018-0142-z

  Prefibrotic myelofibrosis (pre-PMF) is a distinct entity among chronic myeloproliferative neoplasm diagnosed according to the revised 2016 WHO classification. […] Each patient should be evaluated for, and interventions adapted to, both life-expectancy and the risk of bleeding and thrombosis. In low-risk patients with expected long survival, observation only is recommended; in cumulated intermediate-1 and -2 risk cases, whose median survival is projected at more than 10 years, treatment is based on symptoms; in high risk cases, with median survival lower than 5 years, intensive management is required. […] A pragmatic approach to address the risk of bleeding and thrombosis includes: no treatment or low-dose aspirin in asymptomatic patients; aspirin or oral anticoagulation if previous arterial or venous thrombosis, and hydroxyurea as first-line cytoreduction in case of thrombocytosis or leukocytosis.

• #15 Prefibrotic myelofibrosis: treatment algorithm 2018 | Blood Cancer Journal

  https://www.nature.com/articles/s41408-018-0142-z

  Prefibrotic myelofibrosis (pre-PMF) is a distinct entity among chronic myeloproliferative neoplasm diagnosed according to the revised 2016 WHO classification. […] Each patient should be evaluated for, and interventions adapted to, both life-expectancy and the risk of bleeding and thrombosis. In low-risk patients with expected long survival, observation only is recommended; in cumulated intermediate-1 and -2 risk cases, whose median survival is projected at more than 10 years, treatment is based on symptoms; in high risk cases, with median survival lower than 5 years, intensive management is required. […] A pragmatic approach to address the risk of bleeding and thrombosis includes: no treatment or low-dose aspirin in asymptomatic patients; aspirin or oral anticoagulation if previous arterial or venous thrombosis, and hydroxyurea as first-line cytoreduction in case of thrombocytosis or leukocytosis.

• #16 Prefibrotic myelofibrosis: treatment algorithm 2018 | Blood Cancer Journal

  https://www.nature.com/articles/s41408-018-0142-z

  Prefibrotic myelofibrosis (pre-PMF) is a distinct entity among chronic myeloproliferative neoplasm diagnosed according to the revised 2016 WHO classification. […] Each patient should be evaluated for, and interventions adapted to, both life-expectancy and the risk of bleeding and thrombosis. In low-risk patients with expected long survival, observation only is recommended; in cumulated intermediate-1 and -2 risk cases, whose median survival is projected at more than 10 years, treatment is based on symptoms; in high risk cases, with median survival lower than 5 years, intensive management is required. […] A pragmatic approach to address the risk of bleeding and thrombosis includes: no treatment or low-dose aspirin in asymptomatic patients; aspirin or oral anticoagulation if previous arterial or venous thrombosis, and hydroxyurea as first-line cytoreduction in case of thrombocytosis or leukocytosis.

• #17 Prefibrotic myelofibrosis: treatment algorithm 2018 | Blood Cancer Journal

  https://www.nature.com/articles/s41408-018-0142-z

  A comprehensive management of pre-PMF patients should be addressed both to improving life-expectancy and to prevent vascular complications. […] In pre-PMF asymptomatic patients with low-risk disease, there is no evidence to support the value of any therapeutic intervention and observation alone is usually recommended. […] In patients with previous vascular events, low-dose ASA in arterial or oral anticoagulation in venous thrombosis are recommended. Cytoreductive therapy should be added in the presence of thrombocytosis or leukocytosis and hydroxyurea is the drug of choice. […] Specific prognostic scores for predicting the risk of bleeding and thrombosis in PMF patients are not available. The IPSET-T, that is the prognostic system for thrombosis currently recommended for ET, specifically excluded from the analysis patients re-classified as pre-PMF according to the WHO criteria. Thus, for the time being, a pragmatic approach can be suggested. In pre-PMF patients without a previous history of bleeding or thrombosis, no treatment is the first option. […] In patients with previous bleeding, or high bleeding risk, such as extreme thrombocytosis with acquired von Willebrand disease, ASA should be avoided and HU is the recommended treatment.

• #18 Prefibrotic myelofibrosis: treatment algorithm 2018 | Blood Cancer Journal

  https://www.nature.com/articles/s41408-018-0142-z

  A comprehensive management of pre-PMF patients should be addressed both to improving life-expectancy and to prevent vascular complications. […] In pre-PMF asymptomatic patients with low-risk disease, there is no evidence to support the value of any therapeutic intervention and observation alone is usually recommended. […] In patients with previous vascular events, low-dose ASA in arterial or oral anticoagulation in venous thrombosis are recommended. Cytoreductive therapy should be added in the presence of thrombocytosis or leukocytosis and hydroxyurea is the drug of choice. […] Specific prognostic scores for predicting the risk of bleeding and thrombosis in PMF patients are not available. The IPSET-T, that is the prognostic system for thrombosis currently recommended for ET, specifically excluded from the analysis patients re-classified as pre-PMF according to the WHO criteria. Thus, for the time being, a pragmatic approach can be suggested. In pre-PMF patients without a previous history of bleeding or thrombosis, no treatment is the first option. […] In patients with previous bleeding, or high bleeding risk, such as extreme thrombocytosis with acquired von Willebrand disease, ASA should be avoided and HU is the recommended treatment.

• #19 Prefibrotic myelofibrosis: treatment algorithm 2018 | Blood Cancer Journal

  https://www.nature.com/articles/s41408-018-0142-z

  A comprehensive management of pre-PMF patients should be addressed both to improving life-expectancy and to prevent vascular complications. […] In pre-PMF asymptomatic patients with low-risk disease, there is no evidence to support the value of any therapeutic intervention and observation alone is usually recommended. […] In patients with previous vascular events, low-dose ASA in arterial or oral anticoagulation in venous thrombosis are recommended. Cytoreductive therapy should be added in the presence of thrombocytosis or leukocytosis and hydroxyurea is the drug of choice. […] Specific prognostic scores for predicting the risk of bleeding and thrombosis in PMF patients are not available. The IPSET-T, that is the prognostic system for thrombosis currently recommended for ET, specifically excluded from the analysis patients re-classified as pre-PMF according to the WHO criteria. Thus, for the time being, a pragmatic approach can be suggested. In pre-PMF patients without a previous history of bleeding or thrombosis, no treatment is the first option. […] In patients with previous bleeding, or high bleeding risk, such as extreme thrombocytosis with acquired von Willebrand disease, ASA should be avoided and HU is the recommended treatment.

• #20 Primary myelofibrosis – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/myeloproliferative-neoplasms/primary-myelofibrosis/

  Primary myelofibrosis is a rare chronic disorder diagnosed in an estimated 1 per 100,000 population. […] Long-term exposure to high levels of benzene or very high doses of ionising radiation may increase the risk of primary myelofibrosis in a small number of cases. […] For others treatment is largely supportive and is aimed at preventing complications due to low blood counts and an enlarged spleen (splenomegaly). This involves making every effort to improve your quality of life, by relieving any symptoms of anaemia or an enlarged spleen, and preventing and treating any complications that might arise from your disease or its treatment. […] Antibiotics may be needed to prevent and treat any infections. […] JAK2 inhibitors work by blocking the activity of the JAK2 protein, which may lead to a reduction in splenomegaly and decreased symptoms. They also work in patients with myelofibrosis without the JAK2 mutation.

• #21 Primary myelofibrosis – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/myeloproliferative-neoplasms/primary-myelofibrosis/

  Primary myelofibrosis is a rare chronic disorder diagnosed in an estimated 1 per 100,000 population. […] Long-term exposure to high levels of benzene or very high doses of ionising radiation may increase the risk of primary myelofibrosis in a small number of cases. […] For others treatment is largely supportive and is aimed at preventing complications due to low blood counts and an enlarged spleen (splenomegaly). This involves making every effort to improve your quality of life, by relieving any symptoms of anaemia or an enlarged spleen, and preventing and treating any complications that might arise from your disease or its treatment. […] Antibiotics may be needed to prevent and treat any infections. […] JAK2 inhibitors work by blocking the activity of the JAK2 protein, which may lead to a reduction in splenomegaly and decreased symptoms. They also work in patients with myelofibrosis without the JAK2 mutation.

• #22 Primary myelofibrosis – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/myeloproliferative-neoplasms/primary-myelofibrosis/

  Primary myelofibrosis is a rare chronic disorder diagnosed in an estimated 1 per 100,000 population. […] Long-term exposure to high levels of benzene or very high doses of ionising radiation may increase the risk of primary myelofibrosis in a small number of cases. […] For others treatment is largely supportive and is aimed at preventing complications due to low blood counts and an enlarged spleen (splenomegaly). This involves making every effort to improve your quality of life, by relieving any symptoms of anaemia or an enlarged spleen, and preventing and treating any complications that might arise from your disease or its treatment. […] Antibiotics may be needed to prevent and treat any infections. […] JAK2 inhibitors work by blocking the activity of the JAK2 protein, which may lead to a reduction in splenomegaly and decreased symptoms. They also work in patients with myelofibrosis without the JAK2 mutation.

• #23

  https://link.springer.com/article/10.1007/s11899-024-00729-8

  Furthermore, ruxolitinib can be administered long term, with the opportunity to reintroduce ruxolitinib or use different JAK inhibitors sequentially if discontinuation is required, emphasizing that active treatment options are not used up by starting early. […] Taken together, there is little to no benefit to delaying active treatment in patients with symptomatic lower-risk or int-2/high-risk MF.

• #24 Managing and Mitigating Discontinuation Syndrome With Ruxolitinib and Other Novel JAK Inhibitors for Myelofibrosis

  https://jhoponline.com/issue-archive/2025-issues/february-2025-vol-15-no-1/managing-and-mitigating-discontinuation-syndrome-with-ruxolitinib-and-other-novel-jak-inhibitors-for-myelofibrosis

  Ruxolitinib discontinuation syndrome can be a potential life-threatening complication associated with the abrupt discontinuation of ruxolitinib therapy when used for the treatment of myelofibrosis. Key risk factors associated with ruxolitinib discontinuation syndrome include myelofibrosis disease severity, patient frailty, and hematologic parameters. Mitigating this adverse event can be accomplished by tapering ruxolitinib doses gradually and avoiding abrupt discontinuation. In addition, prophylactic corticosteroids can be considered while tapering ruxolitinib to further aid in preventing this syndrome. […] Although standardized protocols for the identification and management of RDS are still lacking, the identified risk factors for RDS include disease severity, patient frailty, and certain hematologic parameters. The lack of established guidelines necessitates a comprehensive understanding of potential prevention strategies for RDS, including tapering approaches, prophylactic corticosteroids, and close monitoring on discontinuation.

• #25 Managing and Mitigating Discontinuation Syndrome With Ruxolitinib and Other Novel JAK Inhibitors for Myelofibrosis

  https://jhoponline.com/issue-archive/2025-issues/february-2025-vol-15-no-1/managing-and-mitigating-discontinuation-syndrome-with-ruxolitinib-and-other-novel-jak-inhibitors-for-myelofibrosis

  Ruxolitinib discontinuation syndrome can be a potential life-threatening complication associated with the abrupt discontinuation of ruxolitinib therapy when used for the treatment of myelofibrosis. Key risk factors associated with ruxolitinib discontinuation syndrome include myelofibrosis disease severity, patient frailty, and hematologic parameters. Mitigating this adverse event can be accomplished by tapering ruxolitinib doses gradually and avoiding abrupt discontinuation. In addition, prophylactic corticosteroids can be considered while tapering ruxolitinib to further aid in preventing this syndrome. […] Although standardized protocols for the identification and management of RDS are still lacking, the identified risk factors for RDS include disease severity, patient frailty, and certain hematologic parameters. The lack of established guidelines necessitates a comprehensive understanding of potential prevention strategies for RDS, including tapering approaches, prophylactic corticosteroids, and close monitoring on discontinuation.

• #26 Managing and Mitigating Discontinuation Syndrome With Ruxolitinib and Other Novel JAK Inhibitors for Myelofibrosis

  https://jhoponline.com/issue-archive/2025-issues/february-2025-vol-15-no-1/managing-and-mitigating-discontinuation-syndrome-with-ruxolitinib-and-other-novel-jak-inhibitors-for-myelofibrosis

  Therefore, there is a need for standardized approaches to the management of RDS during transitions between JAK inhibitors, which is especially important to consider in an era of novel JAK inhibitors. Clinicians should use the available insights on RDS prevention and management and tailor treatment strategies and interventions to individual patient scenarios, while also seeking optimal standard approaches to care to aim for improved patient outcomes and minimized AEs in the treatment of myelofibrosis. […] To avoid the continued and serious complications of RDS symptoms, clinical trial investigators have recommended careful tapering under supervision since the identification of this complication, which reflects common practice. Avoiding the sudden discontinuation of ruxolitinib is a primary measure that can be used to prevent the occurrence of discontinuation syndrome. Prescribers may seek to taper doses by 5 to 10 mg daily over a 14-day period to a target of at most 10 mg twice daily (if not to a lower dose), especially in patients who have a high risk for rebound symptoms (high disease burden or refractory disease) or in patients who are deemed frail.

• #27 Managing and Mitigating Discontinuation Syndrome With Ruxolitinib and Other Novel JAK Inhibitors for Myelofibrosis

  https://jhoponline.com/issue-archive/2025-issues/february-2025-vol-15-no-1/managing-and-mitigating-discontinuation-syndrome-with-ruxolitinib-and-other-novel-jak-inhibitors-for-myelofibrosis

  Therefore, there is a need for standardized approaches to the management of RDS during transitions between JAK inhibitors, which is especially important to consider in an era of novel JAK inhibitors. Clinicians should use the available insights on RDS prevention and management and tailor treatment strategies and interventions to individual patient scenarios, while also seeking optimal standard approaches to care to aim for improved patient outcomes and minimized AEs in the treatment of myelofibrosis. […] To avoid the continued and serious complications of RDS symptoms, clinical trial investigators have recommended careful tapering under supervision since the identification of this complication, which reflects common practice. Avoiding the sudden discontinuation of ruxolitinib is a primary measure that can be used to prevent the occurrence of discontinuation syndrome. Prescribers may seek to taper doses by 5 to 10 mg daily over a 14-day period to a target of at most 10 mg twice daily (if not to a lower dose), especially in patients who have a high risk for rebound symptoms (high disease burden or refractory disease) or in patients who are deemed frail.

• #28 Managing and Mitigating Discontinuation Syndrome With Ruxolitinib and Other Novel JAK Inhibitors for Myelofibrosis

  https://jhoponline.com/issue-archive/2025-issues/february-2025-vol-15-no-1/managing-and-mitigating-discontinuation-syndrome-with-ruxolitinib-and-other-novel-jak-inhibitors-for-myelofibrosis

  Stopping ruxolitinib soon before the start of conditioning for allogeneic hematopoietic stem-cell transplantation may also prevent RDS. […] The ability to continue treatment with ruxolitinib, or even restart the drug if necessary, may be critical in avoiding severe disease manifestations. […] Discontinuation syndrome has recently become an area of consideration with the approvals of alternative JAK inhibitors after ruxolitinib. First, there have been concerns regarding a similar syndrome with the other JAK inhibitors as with ruxolitinib, but with limited reports to date, which are thought to be in part because of longer half-lives, at least with fedratinib and pacritinib. […] The ultimate strategy will likely depend on the patient- and disease-specific scenarios, but there are limited data that can offer insight into the optimal switching strategy. […] What we can glean from these clinical trial data is that the preferred practice may be to taper ruxolitinib to at least 10 mg twice daily, if not tapering off completely, before switching to an alternative JAK inhibitor at the next dosing time.

• #29 Managing and Mitigating Discontinuation Syndrome With Ruxolitinib and Other Novel JAK Inhibitors for Myelofibrosis

  https://jhoponline.com/issue-archive/2025-issues/february-2025-vol-15-no-1/managing-and-mitigating-discontinuation-syndrome-with-ruxolitinib-and-other-novel-jak-inhibitors-for-myelofibrosis

  Stopping ruxolitinib soon before the start of conditioning for allogeneic hematopoietic stem-cell transplantation may also prevent RDS. […] The ability to continue treatment with ruxolitinib, or even restart the drug if necessary, may be critical in avoiding severe disease manifestations. […] Discontinuation syndrome has recently become an area of consideration with the approvals of alternative JAK inhibitors after ruxolitinib. First, there have been concerns regarding a similar syndrome with the other JAK inhibitors as with ruxolitinib, but with limited reports to date, which are thought to be in part because of longer half-lives, at least with fedratinib and pacritinib. […] The ultimate strategy will likely depend on the patient- and disease-specific scenarios, but there are limited data that can offer insight into the optimal switching strategy. […] What we can glean from these clinical trial data is that the preferred practice may be to taper ruxolitinib to at least 10 mg twice daily, if not tapering off completely, before switching to an alternative JAK inhibitor at the next dosing time.

• #30 Managing and Mitigating Discontinuation Syndrome With Ruxolitinib and Other Novel JAK Inhibitors for Myelofibrosis

  https://jhoponline.com/issue-archive/2025-issues/february-2025-vol-15-no-1/managing-and-mitigating-discontinuation-syndrome-with-ruxolitinib-and-other-novel-jak-inhibitors-for-myelofibrosis

  Stopping ruxolitinib soon before the start of conditioning for allogeneic hematopoietic stem-cell transplantation may also prevent RDS. […] The ability to continue treatment with ruxolitinib, or even restart the drug if necessary, may be critical in avoiding severe disease manifestations. […] Discontinuation syndrome has recently become an area of consideration with the approvals of alternative JAK inhibitors after ruxolitinib. First, there have been concerns regarding a similar syndrome with the other JAK inhibitors as with ruxolitinib, but with limited reports to date, which are thought to be in part because of longer half-lives, at least with fedratinib and pacritinib. […] The ultimate strategy will likely depend on the patient- and disease-specific scenarios, but there are limited data that can offer insight into the optimal switching strategy. […] What we can glean from these clinical trial data is that the preferred practice may be to taper ruxolitinib to at least 10 mg twice daily, if not tapering off completely, before switching to an alternative JAK inhibitor at the next dosing time.

• #31 Managing and Mitigating Discontinuation Syndrome With Ruxolitinib and Other Novel JAK Inhibitors for Myelofibrosis

  https://jhoponline.com/issue-archive/2025-issues/february-2025-vol-15-no-1/managing-and-mitigating-discontinuation-syndrome-with-ruxolitinib-and-other-novel-jak-inhibitors-for-myelofibrosis

  Stopping ruxolitinib soon before the start of conditioning for allogeneic hematopoietic stem-cell transplantation may also prevent RDS. […] The ability to continue treatment with ruxolitinib, or even restart the drug if necessary, may be critical in avoiding severe disease manifestations. […] Discontinuation syndrome has recently become an area of consideration with the approvals of alternative JAK inhibitors after ruxolitinib. First, there have been concerns regarding a similar syndrome with the other JAK inhibitors as with ruxolitinib, but with limited reports to date, which are thought to be in part because of longer half-lives, at least with fedratinib and pacritinib. […] The ultimate strategy will likely depend on the patient- and disease-specific scenarios, but there are limited data that can offer insight into the optimal switching strategy. […] What we can glean from these clinical trial data is that the preferred practice may be to taper ruxolitinib to at least 10 mg twice daily, if not tapering off completely, before switching to an alternative JAK inhibitor at the next dosing time.

• #32 Managing and Mitigating Discontinuation Syndrome With Ruxolitinib and Other Novel JAK Inhibitors for Myelofibrosis

  https://jhoponline.com/issue-archive/2025-issues/february-2025-vol-15-no-1/managing-and-mitigating-discontinuation-syndrome-with-ruxolitinib-and-other-novel-jak-inhibitors-for-myelofibrosis

  Stopping ruxolitinib soon before the start of conditioning for allogeneic hematopoietic stem-cell transplantation may also prevent RDS. […] The ability to continue treatment with ruxolitinib, or even restart the drug if necessary, may be critical in avoiding severe disease manifestations. […] Discontinuation syndrome has recently become an area of consideration with the approvals of alternative JAK inhibitors after ruxolitinib. First, there have been concerns regarding a similar syndrome with the other JAK inhibitors as with ruxolitinib, but with limited reports to date, which are thought to be in part because of longer half-lives, at least with fedratinib and pacritinib. […] The ultimate strategy will likely depend on the patient- and disease-specific scenarios, but there are limited data that can offer insight into the optimal switching strategy. […] What we can glean from these clinical trial data is that the preferred practice may be to taper ruxolitinib to at least 10 mg twice daily, if not tapering off completely, before switching to an alternative JAK inhibitor at the next dosing time.

• #33 https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment/supportive-care

  https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment/supportive-care

  Supportive care is given to improve the quality of life for patients with MF. The goal of supportive care is to prevent or treat the symptoms of MF. […] Treatment recommendations for patients who have MF with anemia include: […] There are several options for dealing with the painful effects of an enlarged spleen, which include: […] Benefits include a reduction of symptoms, decreased portal hypertension and less need for red blood cell transfusions.

• #34 https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment/supportive-care

  https://www.lls.org/myeloproliferative-neoplasms/myelofibrosis/treatment/supportive-care

  Supportive care is given to improve the quality of life for patients with MF. The goal of supportive care is to prevent or treat the symptoms of MF. […] Treatment recommendations for patients who have MF with anemia include: […] There are several options for dealing with the painful effects of an enlarged spleen, which include: […] Benefits include a reduction of symptoms, decreased portal hypertension and less need for red blood cell transfusions.

• #35 Myelofibrosis; Treatment, Prevention & Management | Massive Bio

  https://massivebio.com/myelofibrosis-treatment-prevention-management/

  Myelofibrosis cannot be avoided, although allogeneic hematopoietic cell transplantation (HCT) may offer a treatment. The treatment entails replacing a patients immune system with that of an appropriate donor. This new immune system searches for and kills malignant cells in the myelofibrosis patients bone marrow while still providing healthy blood-making bone marrow cells. Prior to the transplant, the patient must undergo chemotherapy and/or radiation therapy to weaken his or her own immune system so that the donors cells can take. […] HCT is associated with a high risk of complications and is only appropriate for specific people. Complications are more likely in people who have other medical issues. For individuals who may be candidates for the surgery, several variables must be considered, including their age, the intensity of their symptoms, potential risk factors, and the possibility of success.

• #36 Myelofibrosis; Treatment, Prevention & Management | Massive Bio

  https://massivebio.com/myelofibrosis-treatment-prevention-management/

  Myelofibrosis cannot be avoided, although allogeneic hematopoietic cell transplantation (HCT) may offer a treatment. The treatment entails replacing a patients immune system with that of an appropriate donor. This new immune system searches for and kills malignant cells in the myelofibrosis patients bone marrow while still providing healthy blood-making bone marrow cells. Prior to the transplant, the patient must undergo chemotherapy and/or radiation therapy to weaken his or her own immune system so that the donors cells can take. […] HCT is associated with a high risk of complications and is only appropriate for specific people. Complications are more likely in people who have other medical issues. For individuals who may be candidates for the surgery, several variables must be considered, including their age, the intensity of their symptoms, potential risk factors, and the possibility of success.

• #37 Myelofibrosis: Symptoms, Causes, Diagnosis, and Treatment

  https://www.webmd.com/cancer/myelofibrosis-causes-risk-factors

  Theres no way to prevent myelofibrosis. But researchers are trying to learn more about it. […] Your treatment will depend on your case, including your symptoms. If you dont have any, your doctor might recommend waiting and watching for changes. […] See your doctor regularly to check your blood for any problems. About 20% of people with myelofibrosis could get acute myeloid leukemia, a kind of cancer thats harder to treat.

• #38 Myelofibrosis: Symptoms, Causes, Diagnosis, and Treatment

  https://www.webmd.com/cancer/myelofibrosis-causes-risk-factors

  Theres no way to prevent myelofibrosis. But researchers are trying to learn more about it. […] Your treatment will depend on your case, including your symptoms. If you dont have any, your doctor might recommend waiting and watching for changes. […] See your doctor regularly to check your blood for any problems. About 20% of people with myelofibrosis could get acute myeloid leukemia, a kind of cancer thats harder to treat.

• #39 Myelofibrosis: Symptoms, Causes, Diagnosis, and Treatment

  https://www.webmd.com/cancer/myelofibrosis-causes-risk-factors

  Theres no way to prevent myelofibrosis. But researchers are trying to learn more about it. […] Your treatment will depend on your case, including your symptoms. If you dont have any, your doctor might recommend waiting and watching for changes. […] See your doctor regularly to check your blood for any problems. About 20% of people with myelofibrosis could get acute myeloid leukemia, a kind of cancer thats harder to treat.

Zobacz więcej